| Literature DB >> 32429211 |
Marina V Kuznetsova1, Julia S Gizatullina1, Larisa Yu Nesterova1, Marjanca Starčič Erjavec2.
Abstract
Escherichia coli strains isolated from case of colibacillosis in Russian poultry farms in the region of Perm Krai were analyzed for their sensitivity to main antibiotics and bacteriocins. Sensitivity profiles for 9 antibiotics and 20 bacteriocins were determined with the disc diffusion method and the overlay test, respectively. Further, with the PCR the presence of several bla and integron 1 genes was revealed and the phylogenetic group for each strain determined. Among the 28 studied E. coli strains 85.7% were resistant to at least three antibiotics, 53.6% to five or more drugs, and 10.7% to eight antibiotics. PCR revealed that the blaTEM gene was harbored by 71.4% of strains and the blaCTX-M gene by 53.6% of strains. The class 1 integrons were found in 28.6% of strains. All of the studied strains were insensitive to ten or more bacteriocins. More than 90% of the studied strains were insensitive to pore-forming colicins of group A and B colicins, while 60.7% were insensitive to colicins with DNase and RNase activity. All of the analyzed strains were insensitive to at least two of the tested microcins. Neither the antibiotic resistance profile nor the bacteriocin resistance profile correlated with phylogenetic group of the strains. Thus, the studied strains were shown to possess high levels of multiple resistance to antibiotics and insensitivity to bacteriocins.Entities:
Keywords: antibiotics; avian Escherichia coli; bacteriocins; colicins; microcins
Year: 2020 PMID: 32429211 PMCID: PMC7285186 DOI: 10.3390/microorganisms8050741
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Agricultural farms and samples.
| Year | Agricultural Farm | |||||
|---|---|---|---|---|---|---|
| Farm 1 (Broiler) | Farm 2 (Parent Flock) | Farm 3 (Broiler) | ||||
| 2016 | 43 (6) | 36 | 21 (3) | 18 | 25 (3) | 15 |
| 2017 | 26 (4) | 22 | 29 (12) | 26 | 27 (5) | 24 |
| 2018 | 18 (2) | 13 | 35 (11) | 22 | 26 (4) | 20 |
All obtained data of the studied strains.
| Strain | Isolation Month, Year | Poultry Farm | Organ Sample | Phylogroup | Bacteriocin Production (+) | Insensitive to Antibiotics (+) | Presence of ESBL and Class 1 Integron Genes (+) | Insensitive to Bacteriocins (+) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amikacin | Gentamicin | Tetracycline | Ciprofloxacin | Levofloxacin | Co-trimoxazole | Ampicillin | Cefotaxime | Ceftazidime | TEM | SHV | OXA | CTX-M | CMY | 3/5cs | ColA | ColB | ColD | ColE1 | ColE2 | ColE3 | ColE4 | ColE5 | ColE6 | ColE7 | ColIa | ColIb | ColK | ColN | mccB17 | ColM | ColS4 | mccC7 | ColV | ColE8J | ||||||
| 4 | Apr 16 | 1 | Liver | U | - | - | - | + | - | - | - | - | - | + | - | - | - | - | - | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| 5 | Apr 16 | 2 | Kidney | B1 | + | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | + | + | + | + | + | + | + | + | + | + | + | + | - | + | - | + | + | + | + | + |
| 7 | May 16 | 1 | Liver | B1 | - | - | - | + | - | - | + | + | - | - | + | - | - | + | - | + | + | + | + | + | - | + | - | + | - | + | + | + | + | + | + | + | + | + | + | - |
| 9 | May 16 | 1 | Lungs | E | + | - | + | + | - | - | + | + | + | + | + | - | - | + | - | - | + | + | + | + | - | - | - | + | - | + | + | + | + | + | - | + | + | + | + | - |
| 11 | Sept 17 | 2 | Liver | B2 | - | - | + | - | - | - | + | + | - | - | + | - | - | + | - | - | + | + | + | + | + | + | - | - | - | + | + | + | + | + | + | + | + | + | + | - |
| 12 | Sept 17 | 2 | Oviduct | C | + | - | + | + | + | + | + | + | - | - | + | - | - | + | - | - | + | + | + | + | + | - | - | + | - | - | + | + | - | + | + | + | + | + | + | + |
| 15 | Oct 17 | 2 | Spleen | B2 | + | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | + | + | + | + | - | + | - | + | + | - | + | + | + | + | + | + | + | + | - | |
| 16 | Oct 17 | 2 | Lungs | D | - | - | - | + | - | - | + | + | - | - | + | - | - | - | - | - | + | + | + | - | - | - | + | - | - | + | + | - | + | + | + | + | + | + | - | |
| 17 | Oct 17 | 2 | Oviduct | F | + | - | - | + | - | - | + | + | - | - | + | - | - | - | - | - | + | + | + | + | + | + | - | + | + | - | + | + | + | + | + | + | + | + | + | + |
| 20 | Oct 17 | 2 | Liver | E | + | - | - | - | + | + | + | + | - | - | + | - | - | + | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| 21 | Oct 17 | 1 | Lungs | F | - | - | - | + | - | - | + | + | - | - | + | - | - | + | - | + | + | + | + | + | - | + | - | + | - | + | + | + | + | + | + | + | + | + | + | - |
| 24 | Nov 17 | 3 | Heart | B1 | + | - | + | + | + | + | + | + | + | + | + | - | - | - | - | - | + | + | + | + | + | - | - | - | - | + | + | + | - | + | + | + | + | + | + | - |
| 26 | Nov 17 | 3 | Lungs | E | + | - | + | + | + | + | + | + | + | + | + | - | - | + | - | - | + | + | + | + | + | + | - | - | - | - | + | + | + | + | + | + | + | + | + | - |
| 29 | Nov 17 | 3 | Liver | E | + | + | + | + | + | + | + | + | - | - | + | - | - | - | - | - | + | + | + | + | + | - | - | + | - | + | + | + | + | + | + | + | - | + | - | + |
| 31 | Nov 17 | 3 | Liver | B1 | - | - | - | + | + | + | + | + | - | - | + | - | - | + | - | + | + | + | + | + | - | - | - | - | - | - | + | + | - | + | + | + | + | + | + | - |
| 33 | Dec 17 | 2 | Heart | B1 | + | + | + | + | + | + | + | + | - | - | + | - | - | + | - | + | + | + | + | + | - | + | - | + | + | - | + | + | + | + | + | + | + | + | + | - |
| 35 | Dec 17 | 1 | Spleen | B2 | + | - | + | + | + | + | + | + | - | - | + | - | - | - | - | - | + | + | + | - | - | - | - | - | - | - | + | + | - | + | + | + | + | + | + | - |
| 36 | Dec 17 | 1 | Liver | B1 | + | - | - | + | + | + | - | + | - | - | + | - | - | + | - | - | - | + | + | + | + | + | + | + | + | + | + | + | - | + | + | + | + | + | + | - |
| 37 | Feb 18 | 1 | Liver | U | + | + | + | + | + | - | + | + | + | + | - | - | - | + | - | - | + | + | + | - | - | - | + | + | - | - | + | + | + | + | - | + | - | + | + | - |
| 41 | Feb 18 | 1 | Lungs | U | - | - | + | + | + | + | + | - | - | - | - | - | - | - | - | - | + | + | + | + | - | + | - | - | - | + | + | + | - | + | + | + | + | + | + | - |
| 42 | Mar 18 | 2 | Kidney | B1 | + | - | - | + | - | - | + | + | - | - | - | - | - | - | - | - | + | + | + | + | - | - | - | + | - | - | + | + | - | + | + | + | + | + | + | - |
| 43 | Mar 18 | 2 | Lungs | B2 | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | + | + | + | + | - | - | - | - | - | + | + | + | + | - | + | + | + | + | + |
| 45 | Mar 18 | 3 | Trachea | C | - | - | - | + | + | + | + | + | - | - | - | + | - | - | - | + | + | + | + | + | - | - | - | - | - | + | + | + | - | + | + | + | + | + | + | - |
| 46 | Mar 18 | 3 | Liver | B1 | + | - | - | + | + | + | + | + | - | - | + | - | - | - | - | - | + | + | + | + | - | - | + | - | + | - | + | + | - | + | + | + | + | + | + | - |
| 11/16 | May 16 | 2 | Liver | A | + | - | + | + | - | - | + | + | + | + | + | - | - | + | - | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | + | + | + | + | + |
| 13/16 | May 16 | 2 | Kidney | A | + | - | + | + | - | - | + | + | + | + | + | - | - | + | - | + | + | + | + | - | + | - | + | - | + | + | - | + | + | + | + | + | + | + | - | |
| 14/16 | May 16 | 2 | Liver | U | + | - | + | - | - | - | + | + | + | + | + | - | - | + | - | - | + | + | + | + | - | + | - | - | - | + | + | + | - | + | + | + | + | + | + | - |
| 20/16 | May 16 | 2 | Lungs | U | + | - | - | - | + | + | + | + | - | - | + | - | - | - | - | + | + | + | + | + | + | - | - | - | - | - | + | + | - | + | + | + | + | + | + | - |
Prevalence of resistance to antibiotics among studied strains.
| Antibiotic | Antibiotic Group | Inhibition Zone for Resistant Isolates (mm) (Disk Diffusion Method) | Disk Antibiotic Content (µg) | Resistant Strains (%) |
|---|---|---|---|---|
| Amikacin | Aminoglycosides | <15 | 30 | 10.7 |
| Gentamicin | Aminoglycosides | <14 | 10 | 46.4 |
| Tetracycline | Tetracyclines | <12 | 30 | 78.6 |
| Ciprofloxacin | Quinolones | <24 | 5 | 50.0 |
| Levofloxacin | Quinolones | <19 | 5 | 46.4 |
| Co-trimoxazole | Trimethoprim/Sulphonamides | <11 | 1.25/23.75 | 82.1 |
| Ampicillin | β-Lactams | <14 | 10 | 82.1 |
| Cefotaxime | β-Lactams | <17 | 5 | 42.9 |
| Ceftazidime | β-Lactams | <19 | 10 | 39.3 |
Prevalence of insensitivity to bacteriocins among studied strains.
| Bacteriocin | Bacteriocin Group | Insensitive Strains (%) |
|---|---|---|
| A | Group A colicins | 96.4 |
| K | Group A colicins | 53.6 |
| N | Group A colicins | 100 |
| S4 | Group A colicins | 92.9 |
| E1 | Group A colicins | 85.7 |
| E2 | Group A colicins | 46.4 |
| E3 | Group A colicins | 53.6 |
| E4 | Group A colicins | 25.0 |
| E5 | Group A colicins | 60.7 |
| E6 | Group A colicins | 32.1 |
| E7 | Group A colicins | 53.6 |
| E8J | Group A colicins | 28.6 |
| B | Group B colicins | 100 |
| Ia | Group B colicins | 100 |
| Ib | Group B colicins | 96.4 |
| D | Group B colicins | 100 |
| M | Group B colicins | 100 |
| B17 | Class I microcins | 78.6 |
| C7 | Class I microcins | 100 |
| V | Class II microcins | 96.4 |